A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Servier
Pfizer
Bristol-Myers Squibb
Bristol-Myers Squibb
Gilead Sciences
Pfizer
Hoffmann-La Roche
Merck Sharp & Dohme LLC
EpicentRx, Inc.
Celgene
Celgene
Celgene